Catalog #SIM0042
InVivoSIM anti-human IL-13 (Tralokinumab Biosimilar)
Clone
Tralokinumab
Reactivities
Human, Monkey
Isotype
Human IgG4, λ
Product Description
This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Tralokinumab, making it ideal for research use. Tralokinumab is a fully humanized IgG4 monoclonal antibody that reacts with interleukin-13 (IL-13). IL-13 is an inflammatory cytokine that is involved in allergic inflammation and the immune response to parasite infection and is regarded as the primary driver of atopic dermatitis. IL-13 interacts with its high-affinity decoy receptors IL13R1 and IL13R2, and the interaction follows the extracellular IL-13’s internalization and depletion. IL-13 binding to heterodimeric IL-4Rα and IL-13Rα1 activates downstream JAK/STAT pathways. IL-13 stimulates B-cell proliferation and the activation of eosinophils, basophils, and mast cells. IL-13 regulates IL-33 through modulation of the production of interleukin-1 receptor-like 1 (IL1RL1), and IL-13 also regulates the synthesis of interferon-gamma (IFNγ) by synergizing with IL-2. IL-13 antagonizes the Th1-driven proinflammatory immune response and downregulates the synthesis of many proinflammatory cytokines, including IL1, IL6, IL10, IL12, and TNF-alpha. Tralokinumab neutralizes the activity of IL-13 by blocking its interaction with both the IL-13Rα1/IL-4Rα receptor complex and IL-13Rα2 receptors. Tralokinumab binds to IL-13 through an epitope that overlaps the IL-13Rα1 and ILRα2 receptors’ binding sites, thereby preventing binding of IL-13. However, the IL-13 binding affinity to the IL-13Rα2 receptor is greater than that of Tralokinumab. Consequently, freed IL-13 remains able to connect to the IL-13Rα2 receptor. Experiments involving Tralokinumab have reported this antibody to functionally neutralize IL-13, i.e., IL-13Rα1:IL-4Rα interactions in vitro in a range of cell-based assays. In related in vivo experiments involving humanized mouse and cynomolgus monkey antigen challenge models, Tralokinumab was shown to inhibit airway hyperresponsiveness and bronchoalveolar lavage eosinophilia.
Specifications
| Isotype | Human IgG4, λ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Mutations | S228P |
| Immunogen | Human IL-13 |
| Reported Applications |
in vivo functional assays in vitro functional assays ELISA Flow cytometry |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL gel clotting assay |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from cell culture supernatant in an animal-free facility |
| Molecular Weight | 150 kDa |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |